🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jonathan R. Fromm

University of Washington

ORCID: 0000-0002-2287-5284

Also affiliated with University of Washington Applied Physics Laboratory

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study”.

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study

The Lancet Haematology(2021)10.1016/s2352-3026(21)00170-8

N/A

1.6DataRank · unranked

59 citations

Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren +15 more

Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL

Blood Advances(2022)10.1182/bloodadvances.2022008628

N/A

0.240DataRank · unranked

3 citations

Ryan C. Lynch, Chaitra S. Ujjani, Ted Gooley, Heather Rasmussen, David G. Coffey +9 more

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7561

N/A

0DataRank · unranked

1 citations

Jonathan R. Fromm, Min Fang, Brian G. Till, Mazyar Shadman, Andrew J. Cowan +11 more

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells

Cancer Biology & Therapy(2024)10.1080/15384047.2024.2314322

N/A

0DataRank · unranked

12 citations

Theo Koob, Jonathan R. Fromm, Ajay K. Gopal, Darrick Carter, Andre Lieber +1 more

Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.e18063

N/A

0DataRank · unranked

1 citations

Vicky Wu, Kevin Ng, Jenna Voutsinas, Ariana Dumenigo‐Jimenez, Jonathan R. Fromm +15 more

Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up

Clinical Lymphoma Myeloma & Leukemia(2023)10.1016/j.clml.2023.10.002

N/A

0DataRank · unranked

12 citations

Ajay K. Gopal, Brian G. Till, Mazyar Shadman, Ryan C. Lynch, Andrew J. Cowan +10 more

Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8 + T-cells despite immune checkpoint signaling

Blood Research(2022)10.5045/br.2022.2021145

N/A

0DataRank · unranked

13 citations

Jonathan R. Fromm, Ajay K. Gopal, A. McGarry Houghton, Adam Greenbaum